Prospective, multi-centric, open label, two arm, parallel group, active control, randomized, comparative clinical study to evaluate efficacy and safety of R-TPR-019 / ReoPro in subjects undergoing percutaneous coronary intervention.

Trial Profile

Prospective, multi-centric, open label, two arm, parallel group, active control, randomized, comparative clinical study to evaluate efficacy and safety of R-TPR-019 / ReoPro in subjects undergoing percutaneous coronary intervention.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Abciximab (Primary)
  • Indications Embolism and thrombosis; Ischaemic heart disorders
  • Focus Therapeutic Use
  • Sponsors Reliance Life Sciences
  • Most Recent Events

    • 26 Jun 2013 Status changed from not yet recruiting to completed as reported by Clinical Trials Registry - India.
    • 21 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top